Zelestra Fast-Tracks 162-MW Solar for Pharma Buyers

• Zelestra powers pharma’s decarbonization with a 162‑MW Cuenca solar cluster delivered early, selling via Schneider’s Energize as Belinchon I–III’s 275,000 modules on trackers boost a 1.1‑GW national portfolio.

Spanish renewables developer Zelestra commissioned a 162-megawatt solar cluster in Cuenca, Castile-La Mancha, ahead of schedule, adding capacity tied to pharmaceutical-sector demand. The Belinchon I, II and III plants were built in under 14 months by Zelestra’s in-house EPC, using 275,000 modules on single-axis trackers. Output is sold via Schneider Electric’s Energize program, which aggregates pharma buyers including Takeda, Teva and UCB with suppliers Avantor, Organon, Perrigo and West Pharmaceutical Services to cut value-chain emissions.

Zelestra’s portfolio in Castile-La Mancha totals 470 MW across nine projects, with 360 MW of solar, wind and batteries in development; national capacity 1.1 GW.

How does Zelestra’s Cuenca solar cluster serve pharma demand via Schneider’s Energize program?

• Uses Schneider Electric’s Energize as an aggregation platform to bundle demand from multiple pharma corporates and their suppliers, creating a single bankable offtake for the Cuenca solar cluster.
  
• Delivers power through virtual PPAs (contract-for-differences) that lock in a fixed price and hedge Iberian spot volatility, while issuing Spanish Guarantees of Origin that are allocated and retired for each buyer.
  
• Enables pharma sponsors to cut Scope 3 emissions by onboarding key suppliers into the same deal, while suppliers convert to market-based Scope 2 reductions without needing standalone credit or procurement teams.
  
• Standardizes contracting, credit support, and settlement via Schneider’s advisory, reducing transaction costs and accelerating time-to-contract for smaller buyers.
  
• Shapes output and settlement across a diversified buyer pool so mid-day solar generation is matched to varied load profiles, improving utilization and minimizing imbalance risk.
  
• Provides traceability and compliance alignment with European EAC rules, allowing cross-border certificate use within the AIB framework to match European pharma loads.
  
• Brings additionality by underwriting new-build capacity; early commissioning pulls forward renewable volumes for upcoming reporting cycles.
  
• Offers optionality for future enhancements (e.g., storage add-ons or granular certificate matching) to improve hourly alignment and firming for critical pharma operations.
  
• Anchors Zelestra’s regional pipeline financeability: aggregated long-term offtake improves lender confidence and reduces the project’s weighted cost of capital, securing durable supply for the pharma cohort.